Axsome Therapeutics Doses First Patient in FOCUS-3 Trial
Axsome Therapeutics announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity disorder, or ADHD.
